DGS Capital Management LLC Purchases 149 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

DGS Capital Management LLC boosted its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 20.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 867 shares of the medical equipment provider’s stock after purchasing an additional 149 shares during the quarter. DGS Capital Management LLC’s holdings in Intuitive Surgical were worth $292,000 at the end of the most recent quarter.

Several other hedge funds have also bought and sold shares of the business. Vanguard Group Inc. grew its position in Intuitive Surgical by 0.7% in the 3rd quarter. Vanguard Group Inc. now owns 29,868,227 shares of the medical equipment provider’s stock valued at $8,730,184,000 after purchasing an additional 196,316 shares during the period. Geode Capital Management LLC grew its position in Intuitive Surgical by 1.0% in the 1st quarter. Geode Capital Management LLC now owns 6,444,995 shares of the medical equipment provider’s stock valued at $1,642,287,000 after purchasing an additional 61,659 shares during the period. Morgan Stanley grew its position in Intuitive Surgical by 29.9% in the 4th quarter. Morgan Stanley now owns 5,866,613 shares of the medical equipment provider’s stock valued at $1,556,706,000 after purchasing an additional 1,351,002 shares during the period. Jennison Associates LLC grew its position in Intuitive Surgical by 6.4% in the 3rd quarter. Jennison Associates LLC now owns 4,585,190 shares of the medical equipment provider’s stock valued at $1,340,205,000 after purchasing an additional 274,692 shares during the period. Finally, Invesco Ltd. grew its position in Intuitive Surgical by 6.6% in the 3rd quarter. Invesco Ltd. now owns 3,750,490 shares of the medical equipment provider’s stock valued at $1,096,231,000 after purchasing an additional 232,205 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Insider Activity

In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The sale was disclosed in a document filed with the SEC, which is available at this link. In other news, Director Alan J. Levy sold 2,000 shares of the company’s stock in a transaction dated Friday, January 26th. The stock was sold at an average price of $370.20, for a total transaction of $740,400.00. Following the sale, the director now directly owns 25,319 shares in the company, valued at $9,373,093.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Mark Brosius sold 196 shares of the company’s stock in a transaction dated Tuesday, March 5th. The shares were sold at an average price of $400.00, for a total value of $78,400.00. Following the sale, the senior vice president now owns 1,842 shares in the company, valued at $736,800. The disclosure for this sale can be found here. Insiders have sold a total of 248,418 shares of company stock worth $95,927,097 over the last ninety days. Company insiders own 0.80% of the company’s stock.

Intuitive Surgical Stock Performance

Shares of Intuitive Surgical stock opened at $378.55 on Wednesday. Intuitive Surgical, Inc. has a 52-week low of $254.85 and a 52-week high of $403.76. The stock’s 50-day simple moving average is $387.90 and its 200 day simple moving average is $342.17. The stock has a market capitalization of $134.18 billion, a P/E ratio of 75.26, a P/E/G ratio of 5.86 and a beta of 1.36.

Intuitive Surgical (NASDAQ:ISRG) last announced its quarterly earnings data on Tuesday, January 23rd. The medical equipment provider reported $1.60 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.48 by $0.12. Intuitive Surgical had a return on equity of 13.11% and a net margin of 25.24%. The business had revenue of $1.93 billion for the quarter, compared to analysts’ expectations of $1.89 billion. During the same period in the previous year, the business posted $0.91 EPS. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. Equities research analysts forecast that Intuitive Surgical, Inc. will post 4.93 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have issued reports on ISRG. Truist Financial lifted their price objective on shares of Intuitive Surgical from $390.00 to $435.00 and gave the stock a “buy” rating in a report on Wednesday, January 24th. Stifel Nicolaus lifted their price objective on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a report on Monday, April 8th. Barclays lifted their price objective on shares of Intuitive Surgical from $385.00 to $430.00 and gave the stock an “overweight” rating in a report on Thursday, January 25th. Mizuho lifted their price objective on shares of Intuitive Surgical from $350.00 to $390.00 and gave the stock a “neutral” rating in a report on Thursday, January 25th. Finally, StockNews.com downgraded shares of Intuitive Surgical from a “buy” rating to a “hold” rating in a report on Thursday, February 29th. Five research analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $375.70.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.